Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Glaxo Adds Alli Warning Label In Europe

This article was originally published in The Tan Sheet

Executive Summary

The European Union health authority recommended GlaxoSmithKline add a warning to alli nonprescription weight-loss drug, advising patients taking levothyroxine or antiepileptic drugs, or those with kidney disease, to consult a doctor before using

You may also be interested in...

FDA Alerts Public To Ongoing Safety Review Of Orlistat In GSK, Roche Drugs

FDA's announcement it is investigating a possible risk of liver injury related to orlistat - the active ingredient in Roche Pharmaceuticals' prescription weight-loss drug Xenical and GlaxoSmithKline's OTC alli - could threaten short-term sales

GSK Upbeat On Alli In EU As Global Consumer Sales Show Healthy Gains

Alli is off to the races in Europe, where it is generating high sales since launching in April, GlaxoSmithKline says

In Europe, Centralized OTC Switch Still Has A Few Bugs

The European Union's diversity means that when it comes to the new centralized procedure for Rx-to-OTC switches, there are several details yet to be ironed out, according to OTC industry executives

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts